Emicizumab: Review of the literature and critical appraisal.
Emérito Carlos Rodríguez MerchánLeonard A ValentinoPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2018)
The principal advantage of emicizumab is subcutaneous administration and effectiveness irrespective of the presence of inhibitors. Emicizumab could conceivably represent a new epoch in the treatment of people with haemophilia A.